← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Allosteros Therapeutics, Inc.
Sunnyvale, CA
$2,736,656
Total funding
8
Grants
Funding over time
peak $1M · FY2011–17$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,736,656 · 8
By mechanism
R43$1,740,772 · 7
R01$995,884 · 1
Investigators at Allosteros Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Ca2+/CaM-Dependent Protein Kinase II: A Novel Target in Osteosarcoma$279,182
R43 · FY2012 · CA
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II$267,039
R01 · FY2014 · GM
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II$257,692
R01 · FY2013 · GM
Developing Ca2+/CaM Kinase II Inhibitors to Treat Arrhythmias in Heart Failure$257,362
R43 · FY2012 · HL
Targeting CaM Kinase II for Neuroprotection in Ischemic Stroke$249,701
R43 · FY2012 · NS
Targeting CaM Kinase II and Oxidative Damage in Allergic Asthma$249,171
R43 · FY2011 · HL
Optimizing active site inhibitor of CaMKII: A Novel Target in Atrial Fibrillation$249,025
R43 · FY2016 · HL
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II$246,115
R01 · FY2012 · GM
Advancing Allosteric CaMKII Inhibitors to Treat Multiple Novel Pathways in Diabetes$243,415
R43 · FY2017 · DK
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II$225,038
R01 · FY2015 · GM
Ca2+/CaM-Dependent Protein Kinase II: A Novel Target in Heart Failure$212,916
R43 · FY2011 · HL